Emmaus Life Sciences Stock Fundamentals
| EMMADelisted Stock | USD 0.26 0.00 0.00% |
Emmaus Life Sciences fundamentals help investors to digest information that contributes to Emmaus Life's financial success or failures. It also enables traders to predict the movement of Emmaus OTC Stock. The fundamental analysis module provides a way to measure Emmaus Life's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Emmaus Life otc stock.
Emmaus |
Emmaus Life Sciences OTC Stock Current Valuation Analysis
Emmaus Life's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Emmaus Life Current Valuation | 49.41 M |
Most of Emmaus Life's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Emmaus Life Sciences is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
CompetitionIn accordance with the recently published financial statements, Emmaus Life Sciences has a Current Valuation of 49.41 M. This is 99.66% lower than that of the Pharmaceuticals sector and 98.94% lower than that of the Health Care industry. The current valuation for all United States stocks is 99.7% higher than that of the company.
Emmaus Life Sciences Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Emmaus Life's current stock value. Our valuation model uses many indicators to compare Emmaus Life value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Emmaus Life competition to find correlations between indicators driving Emmaus Life's intrinsic value. More Info.Emmaus Life Sciences is one of the top stocks in return on asset category among its peers. It also is one of the top stocks in profit margin category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Emmaus Life by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Emmaus Life's OTC Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Emmaus Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Emmaus Life's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Emmaus Life could also be used in its relative valuation, which is a method of valuing Emmaus Life by comparing valuation metrics of similar companies.Emmaus Life is currently under evaluation in current valuation category among its peers.
Emmaus Fundamentals
| Return On Asset | -0.12 | ||||
| Profit Margin | (1.14) % | ||||
| Operating Margin | (0.65) % | ||||
| Current Valuation | 49.41 M | ||||
| Shares Outstanding | 49.56 M | ||||
| Shares Owned By Insiders | 38.73 % | ||||
| Number Of Shares Shorted | 41.22 K | ||||
| Price To Earning | (1.60) X | ||||
| Price To Sales | 1.06 X | ||||
| Revenue | 20.61 M | ||||
| Gross Profit | 17.3 M | ||||
| EBITDA | (12.76 M) | ||||
| Net Income | (15.95 M) | ||||
| Cash And Equivalents | 982 K | ||||
| Cash Per Share | 0.02 X | ||||
| Total Debt | 4.65 M | ||||
| Debt To Equity | (0.04) % | ||||
| Current Ratio | 0.14 X | ||||
| Book Value Per Share | (0.76) X | ||||
| Cash Flow From Operations | (1.25 M) | ||||
| Short Ratio | 0.48 X | ||||
| Earnings Per Share | (0.18) X | ||||
| Target Price | 4.0 | ||||
| Number Of Employees | 58 | ||||
| Beta | 1.97 | ||||
| Market Capitalization | 24.28 M | ||||
| Total Asset | 56.73 M | ||||
| Retained Earnings | (82.78 M) | ||||
| Working Capital | 1.95 M | ||||
| Current Asset | 9.19 M | ||||
| Current Liabilities | 7.25 M | ||||
| Z Score | 1.6 | ||||
| Net Asset | 56.73 M |
About Emmaus Life Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Emmaus Life Sciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Emmaus Life using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Emmaus Life Sciences based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Emmaus Life Sciences, Inc., a commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally. Emmaus Life Sciences, Inc. was founded in 2000 and is headquartered in Torrance, California. Emmaus Life operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 58 people.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in population. You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Other Consideration for investing in Emmaus OTC Stock
If you are still planning to invest in Emmaus Life Sciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Emmaus Life's history and understand the potential risks before investing.
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios |